Related Experiment Video

Updated: Jul 4, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Acute and long-term antiplatelet therapy

Athanasios I Papathanasiou1, John A Goudevenos, Dimitri P Mikhailidis

  • 1Department of Cardiology, Medical School, University of Ioannina, Ioannina, Greece. atselep@uoi.gr

Drugs of Today (Barcelona, Spain : 1998)
|June 13, 2008
PubMed

Insights

Antiplatelet therapy, including aspirin and newer agents, is crucial for managing atherothrombotic vascular disease. This review summarizes key trials and recommendations for effective and safe antiplatelet treatment.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Atherothrombotic vascular diseases (e.g., acute coronary syndromes, stroke) are leading causes of death globally.
  • Platelet activation and aggregation are central to the development and manifestation of these conditions.
  • Antiplatelet therapy significantly improves outcomes for patients with established atherothrombotic disease.

Purpose of the Study:

  • To review major clinical trials on antiplatelet therapy for atherothrombotic disease.
  • To summarize current recommendations for the efficacy and safety of these treatments.
  • To provide an overview of established and newer antiplatelet agents.

Main Methods:

  • Literature review of landmark clinical trials.
  • Analysis of efficacy and safety data for antiplatelet agents.
  • Synthesis of current clinical practice guidelines and recommendations.

Main Results:

  • Aspirin remains a cornerstone, with similar effectiveness shown for adenosine diphosphate (ADP) receptor antagonists (clopidogrel, ticlopidine) and glycoprotein (GP) IIb/IIIa inhibitors.
  • These agents improve outcomes in patients with established atherothrombotic vascular disease.
  • The review covers efficacy and safety profiles based on major clinical studies.

Conclusions:

  • Antiplatelet therapy is essential for managing atherothrombotic vascular disease.
  • Multiple drug classes, including aspirin, ADP antagonists, and GP IIb/IIIa inhibitors, are effective.
  • Understanding trial data and recommendations is key for optimizing patient care and safety.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...